通过结合基线PET/CT总代谢瘤体积,病变扩散和TP53突变来预测扩散性大B细胞淋巴瘤的快速进展,建立了一个名图

Cong Liu1,2,3, Pengyue Shi4, Zhenjiang Li5

  • 1National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Cancer medicine
|June 27, 2023
PubMed
概括

整合PET/CT成像指标和TP53基因突变可以改善扩散型大B细胞淋巴瘤 (DLBCL) 患者的风险分层. 这种综合方法提高了针对量身定制治疗的无进展生存率的预测.